Stocks in play: Fennec Pharmaceuticals Inc.

Announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,596,190 entitled “Method for Reducing Ototoxicity in Pediatric Patients Receiving Platinum-Based Chemotherapy.” As suggested by the title, the patent captures the use of Fennec’s PEDMARK product to reduce the ototoxic effects of cisplatin in pediatric patients, particularly in the age group of five years or younger. This is the U.S Food and Drug Administration (FDA) Orange Book eligible U.S. patent, and reflects Fennec’s strategy to expand and diversify its intellectual property portfolio to obtain protection for the PEDMARK product. Fennec Pharmaceuticals Inc. shares T.FRX are trading unchanged at $9.35.

Read: A Multi-Billion-Dollar CBD Opportunity is Quickly Emerging in Latin America